357 related articles for article (PubMed ID: 36798118)
1. Patient-derived monoclonal antibodies to SARS-CoV-2 nucleocapsid protein N-terminal and C-terminal domains cross-react with their counterparts of SARS-CoV, but not other human betacoronaviruses.
Wen Y; Guo W; Min Y; Zhong K; Zhang X; Xing X; Tong Y; Pan Y; Hong W; Cai W; Yu L
Front Immunol; 2023; 14():1093709. PubMed ID: 36798118
[TBL] [Abstract][Full Text] [Related]
2. Monoclonal antibodies constructed from COVID-19 convalescent memory B cells exhibit potent binding activity to MERS-CoV spike S2 subunit and other human coronaviruses.
Peng Y; Liu Y; Hu Y; Chang F; Wu Q; Yang J; Chen J; Teng S; Zhang J; He R; Wei Y; Bostina M; Luo T; Liu W; Qu X; Li YP
Front Immunol; 2022; 13():1056272. PubMed ID: 36618428
[TBL] [Abstract][Full Text] [Related]
3. Identification of the Receptor-Binding Domain of the Spike Glycoprotein of Human Betacoronavirus HKU1.
Qian Z; Ou X; Góes LG; Osborne C; Castano A; Holmes KV; Dominguez SR
J Virol; 2015 Sep; 89(17):8816-27. PubMed ID: 26085157
[TBL] [Abstract][Full Text] [Related]
4. Characterization and application of a series of monoclonal antibodies against SARS-CoV-2 nucleocapsid protein.
Zhou L; Mo C; Yang Y; Zhou Z; You A; Fan Y; Liu W; Li X; Zhou R; Tian X
J Med Virol; 2023 Jan; 95(1):e28225. PubMed ID: 36238992
[TBL] [Abstract][Full Text] [Related]
5. Mapping SARS-CoV-2 Antibody Epitopes in COVID-19 Patients with a Multi-Coronavirus Protein Microarray.
Camerini D; Randall AZ; Trappl-Kimmons K; Oberai A; Hung C; Edgar J; Shandling A; Huynh V; Teng AA; Hermanson G; Pablo JV; Stumpf MM; Lester SN; Harcourt J; Tamin A; Rasheed M; Thornburg NJ; Satheshkumar PS; Liang X; Kennedy RB; Yee A; Townsend M; Campo JJ
Microbiol Spectr; 2021 Oct; 9(2):e0141621. PubMed ID: 34704808
[TBL] [Abstract][Full Text] [Related]
6. Two-way antigenic cross-reactivity between severe acute respiratory syndrome coronavirus (SARS-CoV) and group 1 animal CoVs is mediated through an antigenic site in the N-terminal region of the SARS-CoV nucleoprotein.
Vlasova AN; Zhang X; Hasoksuz M; Nagesha HS; Haynes LM; Fang Y; Lu S; Saif LJ
J Virol; 2007 Dec; 81(24):13365-77. PubMed ID: 17913799
[TBL] [Abstract][Full Text] [Related]
7. Serological profiles of pan-coronavirus-specific responses in COVID-19 patients using a multiplexed electro-chemiluminescence-based testing platform.
Chaudhury S; Hutter J; Bolton JS; Hakre S; Mose E; Wooten A; O'Connell W; Hudak J; Krebs SJ; Darden JM; Regules JA; Murray CK; Modjarrad K; Scott P; Peel S; Bergmann-Leitner ES
PLoS One; 2021; 16(6):e0252628. PubMed ID: 34081747
[TBL] [Abstract][Full Text] [Related]
8. Detection of Serum Cross-Reactive Antibodies and Memory Response to SARS-CoV-2 in Prepandemic and Post-COVID-19 Convalescent Samples.
Shrwani K; Sharma R; Krishnan M; Jones T; Mayora-Neto M; Cantoni D; Temperton NJ; Dobson SL; Subramaniam K; McNamara PS; Cunliffe NA; Turtle L; Zhang Q
J Infect Dis; 2021 Oct; 224(8):1305-1315. PubMed ID: 34161567
[TBL] [Abstract][Full Text] [Related]
9. Epitope mapping of severe acute respiratory syndrome-related coronavirus nucleocapsid protein with a rabbit monoclonal antibody.
Tian X; Mo C; Zhou L; Yang Y; Zhou Z; You A; Fan Y; Liu W; Li X; Zhou R
Virus Res; 2021 Jul; 300():198445. PubMed ID: 33961897
[TBL] [Abstract][Full Text] [Related]
10. Neutralizing and enhancing monoclonal antibodies in SARS-CoV-2 convalescent patients: lessons from early variant infection and impact on shaping emerging variants.
Coutant F; Touret F; Pin JJ; Alonzo M; Baronti C; Munier S; Attia M; de Lamballerie X; Ferry T; Miossec P
Emerg Microbes Infect; 2024 Dec; 13(1):2307510. PubMed ID: 38240255
[TBL] [Abstract][Full Text] [Related]
11. Binding and neutralizing abilities of antibodies towards SARS-CoV-2 S2 domain.
Gao X; Fan L; Zheng B; Li H; Wang J; Zhang L; Li J; Zhu F
Hum Vaccin Immunother; 2022 Nov; 18(5):2055373. PubMed ID: 35417303
[TBL] [Abstract][Full Text] [Related]
12. Monoclonal Antibodies to S and N SARS-CoV-2 Proteins as Probes to Assess Structural and Antigenic Properties of Coronaviruses.
Kumar R; Christensen ND; Kaddis Maldonado RJ; Bewley MC; Ostman A; Sudol M; Chen EC; Buchkovich NW; Gontu A; Surendran Nair M; Nissly RH; Minns AM; Kapur V; Rossi R; Kuchipudi SV; Lindner SE; Parent LJ; Flanagan JM; Buchkovich NJ
Viruses; 2021 Sep; 13(10):. PubMed ID: 34696329
[TBL] [Abstract][Full Text] [Related]
13. N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2.
McCallum M; De Marco A; Lempp FA; Tortorici MA; Pinto D; Walls AC; Beltramello M; Chen A; Liu Z; Zatta F; Zepeda S; di Iulio J; Bowen JE; Montiel-Ruiz M; Zhou J; Rosen LE; Bianchi S; Guarino B; Fregni CS; Abdelnabi R; Foo SC; Rothlauf PW; Bloyet LM; Benigni F; Cameroni E; Neyts J; Riva A; Snell G; Telenti A; Whelan SPJ; Virgin HW; Corti D; Pizzuto MS; Veesler D
Cell; 2021 Apr; 184(9):2332-2347.e16. PubMed ID: 33761326
[TBL] [Abstract][Full Text] [Related]
14. Cross-Neutralization of Emerging SARS-CoV-2 Variants of Concern by Antibodies Targeting Distinct Epitopes on Spike.
Changrob S; Fu Y; Guthmiller JJ; Halfmann PJ; Li L; Stamper CT; Dugan HL; Accola M; Rehrauer W; Zheng NY; Huang M; Wang J; Erickson SA; Utset HA; Graves HM; Amanat F; Sather DN; Krammer F; Kawaoka Y; Wilson PC
mBio; 2021 Dec; 12(6):e0297521. PubMed ID: 34781736
[TBL] [Abstract][Full Text] [Related]
15. Obtaining a high titer of polyclonal antibodies from rats to the SARS-CoV-2 nucleocapsid protein and its N- and C-terminal domains for diagnostic test development.
de Almeida MT; Barbosa AP; Bomfim CG; Visnardi AB; Vinces TC; Ceroni A; Durigon EL; Guzzo CR
J Immunol Methods; 2023 Nov; 522():113558. PubMed ID: 37704125
[TBL] [Abstract][Full Text] [Related]
16. Monoclonal antibodies for the S2 subunit of spike of SARS-CoV-1 cross-react with the newly-emerged SARS-CoV-2.
Zheng Z; Monteil VM; Maurer-Stroh S; Yew CW; Leong C; Mohd-Ismail NK; Cheyyatraivendran Arularasu S; Chow VTK; Lin RTP; Mirazimi A; Hong W; Tan YJ
Euro Surveill; 2020 Jul; 25(28):. PubMed ID: 32700671
[TBL] [Abstract][Full Text] [Related]
17. A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2.
Chi X; Yan R; Zhang J; Zhang G; Zhang Y; Hao M; Zhang Z; Fan P; Dong Y; Yang Y; Chen Z; Guo Y; Zhang J; Li Y; Song X; Chen Y; Xia L; Fu L; Hou L; Xu J; Yu C; Li J; Zhou Q; Chen W
Science; 2020 Aug; 369(6504):650-655. PubMed ID: 32571838
[TBL] [Abstract][Full Text] [Related]
18. The Glycan-Binding Trait of the Sarbecovirus Spike N-Terminal Domain Reveals an Evolutionary Footprint.
Guo H; Li A; Lin HF; Liu MQ; Chen J; Jiang TT; Li B; Wang Y; Letko MC; Peng W; Shi ZL
J Virol; 2022 Aug; 96(15):e0095822. PubMed ID: 35852351
[TBL] [Abstract][Full Text] [Related]
19. Identification of B-Cell Linear Epitopes in the Nucleocapsid (N) Protein B-Cell Linear Epitopes Conserved among the Main SARS-CoV-2 Variants.
Rodrigues-da-Silva RN; Conte FP; da Silva G; Carneiro-Alencar AL; Gomes PR; Kuriyama SN; Neto AAF; Lima-Junior JC
Viruses; 2023 Apr; 15(4):. PubMed ID: 37112903
[TBL] [Abstract][Full Text] [Related]
20. Screening and identification of B cell epitope of the nucleocapsid protein in SARS-CoV-2 using the monoclonal antibodies.
Tian Y; Zhang G; Liu H; Ding P; Jia R; Zhou J; Chen Y; Qi Y; Du J; Liang C; Zhu X; Wang A
Appl Microbiol Biotechnol; 2022 Feb; 106(3):1151-1164. PubMed ID: 35037999
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
